The recent updates in its business plan caused a notable spike in Personalis, Inc. (NASDAQ: PSNL) shares. During Thursday’s regular trading session, PSNL’s shares increased 47.75%, finishing at $5.26. After hours, the stock maintained its upward trajectory, climbing an additional 12.93% to $5.94.
Strategic Partnerships with Merck and Moderna
Personalis revealed it had secured significant partnerships with two prominent collaborators, Merck and Moderna, aimed at advancing its business strategy. Merck has made a $50 million investment, purchasing PSNL common stock at a price of $3.56 per share, the same price as the last recorded closing.
This investment will grant Merck an approximately 16.5% stake in the company. Furthermore, as part of a cooperative initiative with Merck, Personalis and Moderna have extended their partnership to continue developing the V940/mRNA-4157 personalized neoantigen treatment (INT).
The partnership is a crucial component of Personalis’ initiatives to promote the creation of customized cancer treatments, which might completely transform the way that cancer is treated. The ImmunoID NeXT Platform from PSNL will remain essential to the clinical advancement of the experimental treatment.
Expansion with Tempus AI
In addition to its work with Merck and Moderna, Personalis has expanded its commercial relationship with Tempus AI, Inc. To introduce ultra-sensitive minimum residual disease (MRD) testing to the market, the firms initially teamed up in 2023. The partnership was further highlighted during the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Tempus now serves as the exclusive commercial diagnostic partner for Personalis’ NeXT Personal Dx, a product used for MRD testing in breast and lung cancers, as well as immunotherapy monitoring across solid tumors.
Broader Biopharma Reach
Following a positive market response, PSNL and Tempus have agreed to expand their partnership to include biopharma customers. Tempus will now offer the company’s NeXT Personal MRD product alongside its other offerings in biopharma studies.
This expanded collaboration will enhance Personalis’ ability to penetrate the market more effectively, allowing the company to leverage Tempus’ integrated platform and reach a broader audience.
